Showing 11 of 91 recruiting trials for “myelodysplastic-syndrome”
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia
👨⚕️ Liangding Hu, M.D., the Fifth Medical Center the PLA General Hospital📍 1 site📅 Started Jul 2021View details ↗
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
👨⚕️ Antonio Curti, Istituto di Ematologia Seràgnoli, Azienda Ospedaliero-Universitaria di Bologna (IRCCS)📍 1 site📅 Started Jan 2021View details ↗
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
👨⚕️ Benjamin H Tomlinson, Tomlinson, Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RecruitingNCT03275480 ↗
Institut Paoli Calmettes Myelodysplastic Syndromes Database
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RecruitingNCT01311258 ↗
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
← PreviousPage 5 of 5
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →